CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort studyReportar como inadecuado




CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Arthritis Research and Therapy

, 13:R133

First Online: 16 August 2011Received: 28 February 2011Revised: 27 June 2011Accepted: 16 August 2011

Abstract

IntroductionThe aim of our study was to analyze the influence of the CCR5Δ32 polymorphism in the risk of cardiovascular CV events and subclinical atherosclerosis among patients with rheumatoid arthritis RA.

MethodsA total of 645 patients fulfilling the American Rheumatism Association 1987 revised classification criteria for RA were studied. Patients were genotyped for the CCR5 rs333 polymorphism using predesigned TaqMan assays. Also, HLA DRB1 genotyping was performed using molecular-based methods. Carotid intima-media thickness, flow-mediated endothelium-dependent dilatation FMD and endothelium-independent vasodilatation, which were used as surrogate markers of subclinical atherosclerosis, were measured in a subgroup of patients with no clinical CV disease.

ResultsA lower frequency of carriers of the CCR5Δ32 allele among patients with CV events 3.4% versus 11.3%, P = 0.025, odds ratio 0.28, 95% confidence interval 95% CI 0.06 to 0.89 was observed. However, after adjusting for gender, age at time of RA diagnosis, and the presence of shared epitope, rheumatoid factor and classic CV risk factors in the Cox regression analysis, this reduction of CV events in CCR5Δ32 allele carriers was slightly outside the range of significance P = 0.097; hazard ratio 0.37 95% CI 0.12 to 1.19. Carriers of the CCR5Δ32 deletion also showed higher FMD values than the remaining patients CCR5-CCR5Δ32 patients: 7.03% ± 6.61% versus CCR5-CCR5 patients: 5.51% ± 4.66%. This difference was statistically significant when analysis of covariance was performed P = 0.024.

ConclusionsOur results show a potential influence of the CCR5Δ32 deletion on the risk of CV disease among patients with RA. This may be due to a protective effect of this allelic variant against the development of vascular endothelial dysfunction.

Keywordsrheumatoid arthritis atherosclerosis cardiovascular disease genetics CCR5Δ32 rs333 AbbreviationsANCOVAanalysis of covariance

anti-CCPanti-cyclic citrullinated peptide antibodies

bpbase pair

CIconfidence interval

CVcardiovascular

FMDendothelium-dependent flow-mediated vasodilatation postischemia

HLAhuman leukocyte antigen

HRhazard ratio

IMTintima-media thickness

NTGendothelium-independent postnitroglycerin vasodilatation

RArheumatoid arthritis

RFrheumatoid factor

TNFtumor necrosis factor.

Luis Rodríguez-Rodríguez, Carlos González-Juanatey, Mercedes García-Bermúdez contributed equally to this work.

Download fulltext PDF



Autor: Luis Rodríguez-Rodríguez - Carlos González-Juanatey - Mercedes García-Bermúdez - Tomas R Vázquez-Rodríguez - Jose A 

Fuente: https://link.springer.com/







Documentos relacionados